Ablexis Announces Validation and Availability of AlivaMab(R) Mouse-NGX
-
Israelis, Palestinians torn over sacred shrine in city of Hebron
-
In Sudan's Kordofan, a key city reels as paramilitary offensive looms
-
Scheffler to face Hovland in Monday playoff for PGA Travelers title
-
'Burnt out' Stokes leaves England facing tricky questions
-
Germany must win to defy World Cup doubters, says Nagelsmann
-
Critical rescue window closing in Venezuela as quake death toll nears 1,500
-
South Korea's Ryu Hae-ran wins Women's PGA Championship
-
Canada's Marsch praises history-making World Cup 'heroes'
-
Brazil strike confident tone ahead of Japan World Cup clash
-
Co-hosts Canada beat South Africa to reach World Cup last 16 as knockouts begin
-
Israel detonates tunnel, strikes south Lebanon
-
Putin acknowledges fuel shortages after Ukraine strikes
-
Moriyasu praises 'united' Japan on eve of Brazil World Cup clash
-
Canada reach World Cup last 16 as late strike sinks South Africa
-
Looting, theft in Venezuela's earthquake zone add to tragedy
-
Perry stars as Australia knock India out of World Cup
-
Venezuela quakes kill 1,450, time running out to find survivors
-
Stokes 'content' after extraordinary England exit
-
West Indies beat Sri Lanka in first Test
-
Europe swelters as heatwave moves east
-
Asia's World Cup falls apart with just two teams remaining
-
Stokes announces shock England exit as New Zealand eye series win
-
Bromell upsets Lyles, Duplantis shines at Paris Diamond League
-
CAF president Motsepe hails African World Cup successes
-
Man Utd reveal Ugarte knee injury in Uruguay World Cup defeat
-
South Korea coach quits after early World Cup exit
-
Stokes out for 30 in final Test innings after shock England retirement
-
Venezuela quakes kill 1,400, time running out to find survivors
-
Wolff praises 'cold-blooded' Russell, enjoys Antonelli enthusiasm at Austrian GP
-
Hamilton laments lack of power and poor tyre performance
-
Stokes announces shock England exit as Mitchell bats New Zealand into commanding lead
-
Goals galore at record-breaking World Cup
-
Russell overcomes 'tricky run of form' to revive title bid
-
Augusta Tops Best Gold IRA Companies List By Gold Advisor
-
Europe swelters as heatwave moves east, excess deaths rise
-
They support Argentina at the World Cup, but are not Argentine
-
Raducanu hopes to feature at Wimbledon despite injury woe
-
Iran warns ships not to bypass its chosen Hormuz route
-
Russell holds off Verstappen to win Austrian Grand Prix
-
Serena blasts drug test rules ahead of Wimbledon return
-
England captain Stokes to retire from international cricket
-
Ogier wins Acropolis Rally to close in on Evans
-
South Africa maintain World Cup semi-final hopes with nervy win over Bangladesh
-
South Korea president apologises after World Cup group-stage exit
-
Japan's Ogura wins maiden MotoGP as Bezzecchi crashes in Assen
-
Bergs wins Eastbourne final to clinch first ATP title
-
Ravindra and Mitchell strengthen New Zealand's grip on England decider
-
Iran warns challenge to Hormuz routes will spike Middle East tensions
-
BIS warns 'pressure points' putting global economy at risk
-
From rubble to music: Gaza's Oud repairman
Ablexis Announces Validation and Availability of AlivaMab(R) Mouse-NGX
Launching the most advanced transgenic animal platform for human antibody drug discovery
SAN DIEGO, CA / ACCESS Newswire / September 2, 2025 / Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab Mouse technology, today announced the launch of AlivaMab Mouse-NGX, a next-generation suite of advanced transgenic mice that expand both the number and human variable region diversity of antigen-specific antibodies while retaining their requisite drug-like properties.
"AlivaMab Mouse-NGX strains represent a major evolution of our platforms relative to earlier generations of AlivaMab Mouse, which already outperformed other transgenic models and have yielded at least 18 antibodies entered into clinical trials," said Larry Green, Ph.D., Chief Executive Officer of Ablexis. "Our validation tests confirm that AlivaMab Mouse-NGX strains produce up to six-times the number of antigen-specific antibodies while also exhibiting expansion of combinatorial and junctional diversity versus comparator platforms. AlivaMab Mouse-NGX strains set a new benchmark for success in B-cell- and NGS-based human antibody drug discovery," Dr. Green continued.
The AlivaMab Mouse platform is available for use in-house by Ablexis' licensees or exclusively for service provision through AlivaMab Biologics, including access on a license-free, milestone- and royalty-free basis.
About Ablexis, LLC
Ablexis, LLC creates and offers AlivaMab Mouse, a growing suite of unique, patented next generation transgenic mice, as a foundational platform for successful human antibody drug discovery and development. Dozens of companies, including 13 of the world's top 25 global pharmaceutical companies, public and private biotechnology companies, and other entities have licensed AlivaMab Mouse for their antibody drug discovery. Ablexis' sister company, AlivaMab Biologics provides an integrated antibody therapeutic discovery and engineering platform using the AlivaMab Mouse technologies. For more information, please contact us at [email protected].
###
Media Contact:
Maya Tanaka
[email protected]
SOURCE: Ablexis, LLC
View the original press release on ACCESS Newswire
P.Mathewson--AMWN
